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RESUMEN
Los ácidos grasos de la dieta afectan al metabolismo
hepático y la ateroesclerosis mecanismos no revelados
usando una aproximación proteómica.
Los ácidos grasos de la dieta cumplen un importante pa-
pel en la etiología de las enfermedades coronarias. A pesar
de estar bien descrito el efecto de dichos ácidos grasos so-
bre el metabolismo lipoproteíco, no se conocen mecanismos
alternativos que relacionen su influencia sobre posibles en-
fermedades coronarias. En esta revisión se describe el uso
de técnicas proteómicas para la identificación de proteínas
diferencialmente reguladas por dichos ácidos grasos. Tales
proteínas pueden revelar rutas metabólicas implicadas en el
riesgo de enfermedades y reguladas por los ácidos grasos
de la dieta.
PALABRAS CLAVE: Aceite de oliva virgen extra – Ácidos
grasos de la dieta – Aterosclerosis – Metabolismo lipídico
del hígado – Proteómica.
SUMMARY
Dietary fatty acids affecting hepatic metabolism and
atherosclerosis – mechanisms unravelled using a
proteomics approach.
Dietary fatty acids play an important role in the aetiology of
coronary heart disease. The effects of dietary fatty acids on
lipoprotein metabolism are well described, but additional or
alternative mechanisms relating to potential influence on
coronary heart disease are not known. This review describes
how proteomics techniques have been used to identify
proteins that are differentially regulated by dietary fatty acids.
Such proteins may reveal pathways by which dietary fatty
acids influence disease risk.
KEY-WORDS: Atherosclerosis – Dietary fatty acids –
Extra virgin olive oils – Hepatic lipid metabolism –
Proteomics.
1. INTRODUCTION
Over the last few years the complete human
genome sequence has been determined (Lander et
al., 2001). Despite the fact that this achievement is
fundamental to our understanding of cellular
metabolism, it does not show how the cell interacts
with its external environment. Proteins can undergo
posttranslational modifications resulting in multiple
isoforms that may have different biological activities
in cellular metabolism. These alterations may affect
how well a form of the protein interacts with other
proteins or substrates (Livingston et al., 2004). The
complement of proteins in an organism as well 
as their interactions is defined as the proteome.
The proteome is, unlike the genome, dynamic and 
varies according to the cell type and the functional
state of the cell. Proteomics has the advantage over
cDNA micro-arrays that it quantifies the functional
product (protein) of gene expression, and in
addition it allows the identification of protein
modifications that may relate to the activation or
inactivation of proteins by dietary interventions.
Such proteins may not only play a major 
physiological role in a target organ for example, the
liver but could also reflect changes in mechanisms
initiated by dietary intervention when they are
secreted into the circulation.
Currently, proteomic technologies use either
specific digestion of proteins or direct analysis of
intact proteins after their chromatographic
separation. The multiple components of the 
proteome can be analysed by mass spectrometry
(MS) after an evaporation of peptides and protein
by electrospray ionisation (ESI) or matrix-assisted
laser desorption ionisation (MALDI) technologies
(Kim et al., 2004). Classical two-dimensional (2D)
gel electrophoresis, where proteins are separated
according to charge and molecular weight, coupled
with protein spot analysis by mass spectrometry, is
still the most widely used technical approach in
proteomics to identify changes in individual proteins
of tissues, cells and biofluids upon nutritional
intervention (Kim et al., 2004; Fuchs et al., 2005).
While this method is one of the most labour-
intensive of the several types of 2D separation
methods available, it actually yields a physical 
separation of intact polypeptides from each other,
providing information about molecular weight and
iso-electric point. Such parameters can be used to
narrow down the identification of the protein which
can be further analysed by bioinformatics tools
(Barnes and Kim,  2004).
The development of ‘omics’ (genomics,
transcriptomics, proteomics and metabolomics)
technologies in nutrition have opened new 
possibilities to elucidate the complex physiological
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effects of food components, nutrients, or a specific
diet, which are often mediated through multiple 
biochemical and molecular mechanisms.
Furthermore, knowledge about the actions of foods
and nutrients on all possible physiological
outcomes related to, for example, chronic disease
development, is essential to identify dietary
strategies that will promote health and delay the
onset of chronic diseases. Within ‘omics’,
proteomics holds great promise for nutrition
research - proteins are ultimately involved in the
absorption and distribution of nutrients, metabolism
and excretion (Griffiths and Grant, 2006). Here we
review studies of the effects of different dietary fatty
acids on physiological outcome parameters and
mechanistic pathways in the liver using proteomics.
By applying a systems biology analysis we have
identified novel mechanisms by which dietary fats
and fatty acids affect proteins involved in processes
related to coronary heart disease (CHD).
2. DIETARY FATTY ACIDS, LIPOPROTEIN
METABOLISM AND CORONARY HEART
DISEASE
The relationship between diet and CHD, the
major causes of morbidity and mortality in much of
the world today (American Heart Association, 2008),
has been studied intensively. Dietary fatty acids
affect lipoprotein metabolism and their impact on
CHD has traditionally been estimated from their
effects on serum total cholesterol ( Keys et al., 1957;
Hegsted et al., 1965). Indeed, the type of fatty acid
in a diet plays an important role in CHD prevention 
through beneficial or detrimental effect on the
lipoprotein profile (Hu and Willett, 2002). For
example, the Mediterranean diet has been 
associated with a lower risk of CHD, because of its
high content of monounsaturated fat, and because
of a lower general fat intake than in other countries
(Keys et al., 1986; de Lorgeril et al., 1999).
Increased intake of diets rich in polyunsaturated
fatty acids (PUFA) – like those containing a high fish
content, have also been associated with a lower risk
of CHD (Daviglus et al., 1997; Zhang et al., 1999).
Consumption of saturated fatty acids and trans fatty
acids, on the other hand, increase levels of low-
density lipoprotein (LDL) and thereby also the risk 
of CHD (Mensink and Katan, 1992). Current 
recommendations include decreasing the intake of
saturated and trans fats, and increasing the
consumption of omega-3 fatty acids from fish, fish oil
supplements and plant sources as a part of a heart-
healthy diet (Krauss et al., 2000). However, many
issues relating to the intake of dietary fatty acids
other then their effects on lipoprotein metabolism
remain unresolved.
3. EXTRA VIRGIN OLIVE OILS AND
ATHEROSCLEROSIS
Mediterranean populations generally consume a
diet high in extra virgin olive oils (EVOO) that are
rich in monounsaturated fatty acids (MUFA) and
minor antioxidant constituents, mainly phenolic
compounds, which may contribute to a lower risk of
CHD (Ferro-Luzzi and Branca, 1995; Visioli and
Galli, 2002). We have applied a systems biology
approach to gain understanding in mechanisms by
which Picual and Arbequina EVOO may affect
hepatic metabolic pathways, oxidative stress and
eventually atherogenesis (Arbones-Mainar et al.,
2007). Both Picual and Arbequina EVOO decreased
atherosclerotic plaque size after 10 weeks of
intervention in Apoe-/- mice, a model of 
atherosclerosis. Both forms of EVOOs also induced
the accumulation of triglycerides in the liver, without
apparent changes in levels of hepatic -oxidation,
resulting in an increased hepatic fat content and 
liver weight (Arbones-Mainar et al., 2007). These
results imply that olive oils can, on the one hand,
reduce the risk of atherosclerotic plaque formation,
but can also increase the risk of hepatic steatosis. A
systems biology approach was crucial in unravelling
these complex interactions. Using proteomics 
we revealed a significant up-regulation of a large
array of antioxidant enzymes in the liver after 
consumption of extra virgin olive oils (Table 1). Such
GRASAS Y ACEITES, 60 (1), ENERO-MARZO, 28-32, 2009, ISSN: 0017-3495, DOI: 10.3989/gya.086308 29
DIETARY FATTY ACIDS AFFECTING HEPATIC METABOLISM AND ATHEROSCLEROSIS – MECHANISMS UNRAVELLED...
Table 1
Differential regulation of hepatic anti-oxidant enzymes, identified through proteomics, upon consumption
of dietary Picual or Arbequina extra virgin olive (20% w/w) for 10 weeks in Apoe-/- mice.
Antioxidant Enzyme Picual olive oil Arbequina olive oil
Thioredoxin Reductase +200%
Thioredoxin peroxidase 2 +200% +250%
Peroxiredoxin 3 +150%
Superoxide dismutase +250%
Glutathione peroxidase 1 –20%
Glutathione synthase +230%
Glutathione S-transferase +190% +190%
Values represent % up- or downregulation as compared with the dietary palm oil control (20% w/w)
an upregulation could diminish oxidative stress
instigated by hepatic steatosis and thus slow down
the development of atherosclerosis. Therefore
compounds in extra virgin olive oils (such as the
polyphenols) may well be able to delay the onset of
atherosclerotic lesions by preventing excessive
oxidative stress. Indeed, the accumulation of 
triglycerides may not pose a major challenge to the
liver, and represent a relatively safe way to store
triglycerides, as long as the antioxidant capacity is
adequate to prevent lipotoxicity (Arbones-Mainar et
al., 2007).
4. DIFFERENTIAL REGULATION OF TWO
DIETARY CONJUGATED LINOLEIC ACID
ISOMERS
Conjugated linoleic acids (CLA) are a group of
conjugated dieonic isomers of linoleic acid
belonging to ruminant-derived trans fatty acids.
They are present as minor constituents of the lipid
fraction of meat, milk, and dairy products as well
as other foods derived from ruminant animals.
CLA can protect against the development of
atherosclerosis in rabbits (Kritchevsky et al., 2000;
Lee et al., 1994), hamsters (McLeod et al., 2004;
Nicolosi et al., 1997; Wilson et al., 2000) and
transgenic mice (Toomey et al., 2003). The 
mechanisms for this are not well understood, but
might involve modification of the production of
atherogenic lipoproteins by the liver or modification
of inflammatory pathways.
We found that two CLA isomers – almost
structurally identical - had divergent mechanistic
effects on atherosclerosis development and insulin
resistance in Apoe-/- mice. Consumption of trans10,
cis12 CLA, a fatty acid present in many 
supplements that are currently freely available,
was pro-atherogenic and induced pathways
involved in the development of insulin resistance.
This was evident from simultaneous changes in
enzymes involved in gluconeogenesis, lipid
degradation and ketone body formation (de Roos
et al., 2005b). In addition, consumption of the cis
9,trans 11 isomer of CLA resulted in an anti-
diabetic effect, decreased protein levels of pro-
inflammatory macrophage migration inhibitory
factor, and increased expression of anti-
inflammatory HSP 70 kD in liver (de Roos et al.,
2005b). Although one may consider the latter to be
an indication of increased oxidative stress, we
have postulated that up-regulation of HSP 70kD
protein upon exposure to a relatively mild stress
stimulus (like cis9, trans11 CLA) could protect
against exposure to more severe stress. For
example, those related to anti-inflammatory
pathways (mediated through NF-B) (Shimizu et
al., 2002). Indeed, increased levels of human
serum HSP 70 have been associated with a low
coronary artery disease risk, independent of
traditional risk factors (Zhu et al., 2003).
5. DIETARY FATTY ACIDS AND THE HEPATIC
PROTEOME: FISH OIL, TRANS-10, CIS-12
CLA, AND ELAIDIC ACID
How various dietary fatty acids can differentially
affect hepatic protein expression became clear
when we compared the effects of three dietary fatty
acids – fish oil, trans10,cis12 CLA and elaidic acid
– on plasma and liver metabolites and hepatic
proteins in ApoE*3-Leiden transgenic mice (de
Roos et al., 2005a). These mice are a model 
for lipid metabolism, insulin resistance and 
atherosclerosis that are sensitive to changes in
many components of the diet (van Vlijmen et al.,
1994; van Vlijmen et al., 1996; van Vlijmen et al.,
1998). Proteomics of diet-induced changes 
revealed a wide array of hepatic proteins that were
affected by the three dietary fatty interventions.
Significant changes were detected in pathways
involved with glucose and lipid metabolism.This
was consistent with the physiological changes that
occurred in response to the diets. For example, fish
oil, and also trans10, cis12 CLA, increased hepatic
catalase and long chain acyl-CoA thioester
hydrolase proteins, indicative of an increased -
oxidation rate (de Roos et al., 2005a). Long chain
acyl-CoA thioester hydrolase expression had never
been linked to specific dietary fatty acid treatments
before. The suspected increase in -oxidation rates
would explain the lower levels of plasma 
triglycerides and free fatty acids as well as hepatic
triglycerides in the mice after fish oil consumption.
The increase in -oxidation caused by trans10,
cis12 CLA consumption was however indicative of
the development of insulin resistance, since levels
of plasma and hepatic triglycerides, as well as
plasma -hydroxybutyrate and plasma insulin were
significantly increased (de Roos et al., 2005a).
The decrease in hepatic lipid levels in the animals
consuming fish oil and the significant increase in
hepatic triglyceride levels in the trans10, cis12 CLA
group matched with corresponding significant
decreases or increases in levels of hepatic
adipophilin. Adipophilin is associated with lipid
storage droplets that function as deposits for 
triglycerides and cholesterol esters (McManaman et
al., 2003). Increased expression of adipophilin has
been associated with liver steatosis (Heid et al.,
1998), and CLA-mediated liver steatosis has 
occurred in different strains of mice (Clement et al.,
2002; Degrace et al., 2003). Liver steatosis is often
associated with obesity, diabetes, hyperinsulinemia
and VLDL overproduction (den Boer et al., 2004), and
we saw some, but not all, of these associations in our
trans10, cis12 CLA fed mice (de Roos et al., 2005a).
6. DIETARY FISH OIL: EFFECTS ON THE
PLASMA PROTEOME
Dietary intervention may cause changes in
proteins that are secreted into the blood. A major
benefit of the proteomics platform is the non-invasive
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analysis of human body fluids to determine the
consequences of such nutritional interventions.
For example, proteomics studies have the
potential to identify biomarkers for health, to
reveal early indications for disease disposition,
assist in differentiating dietary responders from
non-responders, and to discover beneficial food
components (Kussmann et al., 2006). We have
assessed the effects of dietary fish oil
supplementation for six weeks on the serum 
proteome of healthy subjects. Fish oil, compared with
high oleic sunflower oil supplementation, significantly
down-regulated serum apolipoprotein A1, 
apolipoprotein L1, zinc-α-2-glycoprotein, haptoglobin
precursor, α-1-antitrypsin precursor, anti-thrombin III-
like protein, serum amyloid P component, and
haemopexin. In addition, the decrease in serum
apolipoprotein A1 was associated with a significant
shift towards the larger, more cholesterol-rich HDL2
particles. The alterations in serum proteins and HDL
size imply that fish oil activates anti-inflammatory and
lipid modulating mechanisms believed to impede the
early-onset of CHD. These proteins are potential
diagnostic biomarkers to examine the mechanisms
whereby fish oils protect against CHD in humans (de
Roos et al., 2008).
7. CONCLUSIONS
Proteomics is an emerging and promising tool to
discover the mechanisms of action of nutrients
allied to the identification of new biomarkers of
health or disease. In particular the combination of
proteomics data with physiological parameters,
using correlation analysis as a statistical tool, will 
help to understand how dietary components
regulate several metabolic processes (de Roos et
al., 2005a; de Roos et al., 2005b; Arbones-Mainar
et al., 2007; Milner, 2007). Current proteomics 
approaches in nutrition research mainly include the
use of protein separation, visualisation and 
identification by 2D gel electrophoresis combined
with mass spectrometry (Fuchs et al., 2005).
Despite its limited ability to detect regulation of low
abundant proteins, this approach has already
provided valuable insights in the effects of several
dietary interventions on (relatively abundant)
proteins involved in the regulation of glucose and
fatty acid metabolism, oxidative stress, and the
redox regulation. The ability to measure the 
regulation of more low abundance proteins, such as
those involved in inflammatory pathways, as well as
the evaluation and validation of newly discovered
candidate biomarkers in human biofluids, may
depend on the introduction of more quantitative and
sensitive methods like multiple reaction monitoring
(MRM) and multiplexed immunoassays.
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